The short- and long-term effects of the angiotensin-converting enzyme inhibitor lisinopril and the cardioselective beta-blocker bisoprolol on serum lipids, lipoproteins, apolipoproteins, and lipoprotein(a) (Lp[a]) levels were investigated in patients with mild-to-moderate essential hypertension. Fifty-two patients completed the 12-month, randomized, multicenter trial. After administration of lisinopril (10 to 20 mg/d; n = 24) and bisoprolol (2.5 to 10 mg/d; n = 28), systolic and diastolic blood pressures decreased significantly (P < 0.01) from baseline in both groups at 3, 6, and 12 months. The reduction in diastolic blood pressure was significantly (P < 0.05) greater in the lisinopril group than in the bisoprolol group only at 6 months. Heart rates dropped significantly in the bisoprolol group but not in the lisinopril group. No significant changes in lipids, lipoproteins, apolipoproteins, or Lp(a) levels were observed with either drug at 3, 6, or 12 months, and no significant differences were noted between the two drugs for these parameters. We conclude that lisinopril and bisoprolol are effective as antihypertensive drugs without adverse metabolic effects after short- and long-term treatment in patients with mild-to-moderate essential hypertension.

Adrenergic beta-Antagonists↗

PubMedDate not supplied

In vitro augmentation of natural killer activity of peripheral blood cells from cancer patients by a DNA fraction from Mycobacterium bovis BCG.

Effects of a DNA-rich fraction from Mycobacterium bovis BCG (MY-1) on the natural killer (NK) activity of peripheral blood lymphocytes (PBL) from healthy donors and cancer patients were studied in vitro. The NK activity of PBL was assessed after incubating PBL for 24 hr in the presence or absence of MY-1 or that digested preliminarily with RNase or DNase. One microgram per ml of MY-1 or that digested with RNase augmented the NK activity of PBL from healthy donors. The activity of MY-1 was abolished by the digestion with DNase. Similarly, the NK activity in all of six patients with gastric cancer, 12 patients with colonic cancer, and six patients with uterine cancer was augmented by incubation with MY-1 (1 microgram/ml and 10 micrograms/ml), although the degree of augmentation varied depending upon the origin of PBL.

Colonic Neoplasms↗